Search

Displaying results 4091 - 4100 of 7455 in total
  1. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    [A14416] Additionally, it has been patented for use in development of novel transdermal delivery systems for enhanced drug delivery. … It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.

  2. Drug

    LY-2599506

    go.drugbank.com/drugs/DB05970
    Investigational

    LY2599506 was under investigation in clinical trials NCT01024244 and NCT01029795 for the treatment of patients with type 2 diabetes.

  3. Drug

    AVR118

    go.drugbank.com/drugs/DB04979
    Investigational

    of cancers); for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia … AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment

  4. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD. … Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia.

  5. Drug

    Mecamylamine

    go.drugbank.com/drugs/DB00657
    ApprovedInvestigational

    A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more of...

    Categories: Antihypertensive Agents Indicated for Hypertension
  6. Drug

    SD118

    go.drugbank.com/drugs/DB05207
    Experimental

    for neuropathic pain. … SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy

  7. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  8. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. … It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.

  9. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  10. Drug

    Reproxalap

    go.drugbank.com/drugs/DB16688
    Investigational

    [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990] … Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis